You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

Certaines de ces informations ou toutes, dans certains cas, n’apparaissent qu’en Anglais. Vous pouvez demander la version française

 

210 Results
Regimen
Cancer Type:
Central Nervous System
Intent: Palliative
Funding:
ODB - General Benefit
    temozolomide
Regimen
Cancer Type:
Central Nervous System
Intent: Adjuvant, Palliative
Funding:
ODB - General Benefit
    temozolomide
Regimen
Cancer Type:
Gynecologic, 
Ovary
Intent: Palliative
Regimen
Cancer Type:
Lung, 
Small Cell
Intent: Palliative
Nov 2023
Regimen
Intent: Palliative
Funding:
New Drug Funding Program
    Trastuzumab (Biosimilar) in combination with Chemotherapy - Metastatic Breast Cancer
New Drug Funding Program
    Trastuzumab (Biosimilar) - Second Line - Metastatic Breast Cancer
Regimen
Intent: Adjuvant
Funding:
New Drug Funding Program
    Trastuzumab (Biosimilar) - Adjuvant Treatment for Breast Cancer
Regimen
Cancer Type:
Genitourinary, 
Prostate
Intent: Neoadjuvant, Adjuvant, Palliative
Funding:
ODB - General Benefit
  • triptorelin
Regimen
Cancer Type:
Sarcoma, 
Soft Tissue
Intent: Palliative
Nov 2017
Regimen
Cancer Type:
Genitourinary, 
Testis
Intent: Curative
Mar 2021
Regimen
Intent: Palliative
Funding:
Exceptional Access Program
  • trametinib - As monotherapy in patients with BRAF V600 mutation-positive unresectable or metastatic melanoma, according to specific criteria
Regimen
Cancer Type:
Gynecologic, 
Endometrial, 
Ovary
Intent: Palliative
Funding:
ODB - General Benefit
    tamoxifen
Regimen
Cancer Type:
Gynecologic, 
Ovary
Intent: Palliative

Pages